ESSA Pharma Inc. held a special meeting of securityholders on October 6, 2025. At the meeting, securityholders approved the acquisition of all issued and outstanding common shares of ESSA Pharma Inc. by XenoTherapeutics Inc. Securityholders also approved, in the event the acquisition is terminated, the voluntary liquidation and dissolution of the company, as well as the appointment of PricewaterhouseCoopers LLP or another qualified liquidator, with the board of directors authorized to set the liquidator's remuneration. Completion of the acquisition remains subject to court approval and customary closing conditions, with final approval expected on October 7, 2025, and completion anticipated around October 9, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW (Ref. ID: C1778) on October 06, 2025, and is solely responsible for the information contained therein.